A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells

Rupesh S. Patel, Rodrigo Romero, Emma V. Watson, Anthony C. Liang, Megan Burger, Peter M. K. Westcott, Kim L. Mercer, Roderick T. Bronson, Eric C. Wooten, Arjun Bhutkar, Tyler Jacks and Stephen J. Elledge ()
Additional contact information
Rupesh S. Patel: Brigham and Women’s Hospital
Rodrigo Romero: Massachusetts Institute of Technology
Emma V. Watson: Brigham and Women’s Hospital
Anthony C. Liang: Brigham and Women’s Hospital
Megan Burger: Massachusetts Institute of Technology
Peter M. K. Westcott: Massachusetts Institute of Technology
Kim L. Mercer: Massachusetts Institute of Technology
Roderick T. Bronson: Harvard Medical School
Eric C. Wooten: Brigham and Women’s Hospital
Arjun Bhutkar: Massachusetts Institute of Technology
Tyler Jacks: Massachusetts Institute of Technology
Stephen J. Elledge: Brigham and Women’s Hospital

Nature Communications, 2022, vol. 13, issue 1, 1-13

Abstract: Abstract The GATA4 transcription factor acts as a master regulator of development of multiple tissues. GATA4 also acts in a distinct capacity to control a stress-inducible pro-inflammatory secretory program that is associated with senescence, a potent tumor suppression mechanism, but also operates in non-senescent contexts such as tumorigenesis. This secretory pathway is composed of chemokines, cytokines, growth factors, and proteases. Since GATA4 is deleted or epigenetically silenced in cancer, here we examine the role of GATA4 in tumorigenesis in mouse models through both loss-of-function and overexpression experiments. We find that GATA4 promotes non-cell autonomous tumor suppression in multiple model systems. Mechanistically, we show that Gata4-dependent tumor suppression requires cytotoxic CD8 T cells and partially requires the secreted chemokine CCL2. Analysis of transcriptome data in human tumors reveals reduced lymphocyte infiltration in GATA4-deficient tumors, consistent with our murine data. Notably, activation of the GATA4-dependent secretory program combined with an anti-PD-1 antibody robustly abrogates tumor growth in vivo.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-27731-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-021-27731-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-27731-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().